Former GlaxoSmithKline exec reportedly in line to be White House 'therapeutics czar'

The former head of GlaxoSmithKline's vaccine division, Moncef Slaoui, PhD, will serve as the government's therapeutics czar, a role designed to help speed the development of potential COVID-19 vaccines, Politico reported. 

Dr. Slaoui left GlaxoSmithKline in 2017 and has worked as a venture capitalist since. In his role as therapeutics czar, he will help coordinate the development of COVID-19 vaccines and treatments. 

The position is part of a program the White House calls Operation Warp Speed, designed to drastically cut the time needed to develop a COVID-19 vaccine. 

Dr. Slaoui also sits on the board of Moderna, a drugmaker developing a COVID-19 vaccine, Politico reported. His role as therapeutics czar will be split between HHS and the U.S. Defense Department. 

Read the full article here.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Articles We Think You'll Like